Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS Safety in Severe COVID-19
NCT04513470Phase 1Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Allocetra in coronavirus disease 2019 (COVID-19), sponsored by Hadassah Medical Organization. Primary endpoint: Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE) at 28 days. Status: unknown.
02
Drugs
Allocetra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04513470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513470.